A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

Condition:   Multiple Sclerosis Intervention:   Drug: Natalizumab Sponsor:   Biogen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials